Dyslipidemia in visceral obesity: Mechanisms, implications, and therapy

American Journal of Cardiovascular Drugs

Volumn 4, Issue 4, 2004, Pages 227-246

  Chan, Dick C ^a   Barrett, Hugh P R ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN SENSITIZING AGENT; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; PROTEIN INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL DISCOMFORT; ALCOHOL CONSUMPTION; ATHEROGENESIS; BEHAVIOR MODIFICATION; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG MECHANISM; DYSLIPIDEMIA; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; LIFESTYLE; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; LIVER METABOLISM; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SKIN MANIFESTATION; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; VISCERA; WEIGHT REDUCTION;

ANIMALS; ANTILIPEMIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIFE STYLE; OBESITY;

EID: 4444337145     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404040-00004     Document Type: Review

References (188)

1. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-6
2. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis 1998; 9: 473-81
3. Després JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease. Arterioscler Thromb Vasc Biol 1990; 10: 497-511
4. Borkan GA, Gerzof SG, Robbins AH, et al. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982; 36: 172-7
5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
6. Definition, diagnosis and classification of diabetes mellitus and its complication: Report of a WHO consultation. Geneva, Department of Noncommunicable Disease Surveillance, World Health Organization. 1999
7. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9
8. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16
9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9
10. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738
11. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 Suppl. 3: 24-34
12. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor-α in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95 (5): 2111-21
13. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999; 107: 119-25
14. Nonogaki K, Fuller GM, Fuentes NL, et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 136: 2143-9
15. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
16. Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med 2001; 226: 13-26
17. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-81
18. McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18
19. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-29
20. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447-52
21. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179-84
22. Grundy SM. Metabolic complications of obesity. Endocr J 2000; 13: 155-65
23. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-8
24. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000; 7: 325-31
25. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31
26. Panarotto D, Remillard P, Bouffard L, et al. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 2002; 32: 84-92
27. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans: implications for the insulin-resistant state. Diabetes Care 1996; 19: 390-3
28. Watts GF, Chan DC, Barrett PHR, et al. Adipose tissue compartments and VLDL apolipoprotein B-100 kinetics in overweight-obese men. Obes Res 2003; 11: 152-9
29. Riches FM, Watts GF, Naoumova RP, et al. Hepatic secretion of very-low density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998; 22: 414-23
30. Chan DC, Watts GF, Barrett PH, et al. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002; 48: 278-83
31. Mekki N, Christofilis MA, Charbonnier M, et al. Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women. J Clin Endocrinol Metab 1999; 84: 184-91
32. Ginsberg HN, Illingworth DR. Postprandial dyslipiemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 2001; 88 (6A): 9H-15H
33. Karpe F, de Faire U, Mercuri M, et al. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclersosis 1998; 141: 307-14
34. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997; 38: 2173-92
35. Mamo JC, Watts GF, Barrett PH, et al. Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol 2001; 81: 626-32
36. Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320: 1060-8
37. Kobayashi J, Tashiro J, Murano S, et al. Lipoprotein lipase mass and activity in post-heparin plasma from subjects with intra-abdominal visceral fat accumulation. Clin Endocrinol 1998; 48: 515-20
38. Redgrave TG, Martins IJ, Mortimer BC. Measurement of expired carbon dioxide to access the metabolism of remnant lipoproteins. J Lipid Res 1995; 36: 2670-5
39. Haidari M, Leung N, Mahbub F, et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance: evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 2002; 277: 31646-55
40. Miller M. The epidemiology of triglyceride as a coronary artery disease risk factor. Clin Cardiol 1999; 22: II1-6
41. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9
42. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36
43. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 1997; 8: 146-53
44. Chan DC, Watts GF, Redgrave TG, et al. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002; 29: 1041-6
45. Riches FM, Watts GF, van Bockxmeer FM, et al. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men. J Lipid Res 1998; 39: 1752-8
46. Watts GF, Riches FM, Humphries SE, et al. Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J Lipid Res 2000; 41: 481-8
47. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 2002; 43: 1997-2006
48. Wittrup HH, Hansen AT, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease: a meta-analysis. Circulation 1999; 99: 2901-7
49. Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95: 2022-6
50. Krauss RM, Herbert PN, Levy RI, et al. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res 1973; 33: 403-11
51. Lemieux S, Prud'homme D, Moorjani S, et al. Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men? Atherosclerosis 1995; 118: 155-64
52. Austin MA. Triglyceride, small, dense low density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2: 200-7
53. Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-53
54. Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260 (13): 1917-21
55. Gardner CD, Fortmann SP, Krauss RM. Association of small low density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875-81
56. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062-71
57. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 2002; 252: 440-7
58. Keidar S. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998; 63: 1-11
59. Ailhaud G, Fukamizu A, Massiera F, et al. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes 2000; 24 Suppl. 4: S33-5
60. Keidar S, Kaplan M, Hoffman A, et al. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201-15
61. Fielding C, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211-28
62. Santamarina-Fojo S, Lambert G, Hoeg JM, et al. Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2000; 11: 267-75
63. Fournier N, Myara I, Atger V, et al. Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated high density lipoproteins (HDL). Clin Chim Acta 1995; 234: 47-61
64. Gordon DJ, Prostfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15
65. Assmann G, Schulte H, von Eckardstein A, et al. high density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11-20
66. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high density lipoprotein cholesterol? Curr Opin Lipidol 2000; 11: 627-37
67. Lamarche B, Moorjani S, Cantin B, et al. Association of HDL2 and HDL3 subfractions with ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997; 17: 1098-105
68. Pascot A, Lemieux I, Prud'homme D, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42: 2007-14
69. Lamarche B, Rashid S, Lewis GF. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 1999; 286: 145-61
70. Murakami T, Michelagnoli S, Longhi R, et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995; 15: 1819-28
71. Pascot A, Lemieux I, Bergeron J, et al. HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis 2002; 160: 399-406
72. Pietzsch J, Julius U, Nitzsche S, et al. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998; 47: 1928-34
73. Frenais R, Ouguerram K, Maugeais C, et al. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia 1997; 40: 578-83
74. Pont F, Duvillard L, Florentin E, et al. high density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients: an in vivo stable isotope study. Int J Obes 2002; 26: 1151-8
75. Watts GF, Barrett PHR, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52: 803-11
76. Despres JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153: 263-72
77. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-8
78. American Diabetes Association. Management of dyslipidaemia in adults with diabetes. Diabetes Care 2002; 25: S74-7
79. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans Affairs high density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8
80. The Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21-7
81. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
82. Srinivasan SR, Berenson GS. Apolipoproteins B and A-I as predictors of risk of coronary artery disease. Lancet 2001; 358: 2012-3
83. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33
84. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995; 141: 1128-41
85. Singh RB, Rastogi SS, Verna R, et al. Randomized controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992; 304: 1015-9
86. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
87. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21: S5-9
88. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56: 320-8
89. Riches FM, Watts GF, Hua J, et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999; 84: 2854-61
90. Siscovick DS, Ekelund LG, Hyde JS, et al. Physical activity and coronary heart disease among asymptomatic hypercholesterolemic men (the Lipid Research Clinics Coronary Primary Prevention Trial). Am J Public Health 1988; 78: 1428-31
91. Westheim A, Os I. Physical activity and the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol 1992; 20 Suppl. 8: S49-53
92. Couillard C, Despres JP, Lamarche B, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001; 21: 1226-32
93. Halbert JA, Silagy CA, Finucane P, et al. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 1999; 53: 514-22
94. Zmuda JM, Yurgalevitch SM, Flynn MM, et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis 1998; 137: 215-21
95. Stefanick ML. Physical activity for preventing and treating obesity-related dislipoproteinemias. Med Sci Sport Exerc 1999; 31: S609-18
96. Pearson TA. Alcohol and heart disease. Circulation 1996; 94: 3023-5
97. De Oliveira E Silva ER, Foster D, McGee Harper M, et al. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation 2000; 102: 2347-52
98. Malmendier CL, Delcroix C. Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clin Chim Acta 1985; 152: 281-8
99. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002; 143: 356-65
100. Mori TA, Beilin LJ. Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 2001; 12: 11-7
101. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-57
102. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71: 1085-94
103. Dunstan DW, Mori TA, Puddey IB, et al. The independent and combined effects of aerobic exercise and dietary fish intake or serum lipids and glycemic control in NIDDM: a randomized controlled study. Diabetes Care 1997; 20: 913-21
104. EUROASPIRE I and II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principle results from EUROASPIRE II Euro Heart Survey. Eur Heart J 2001; 22: 554-72
105. Pearson TA, McBride PE, Millet NH, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events: Task Force 8. organization of preventive cardiology service. J Am Coll Cardiol 1996; 27: 1039-47
106. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32: 665-72
107. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
108. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-9
109. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
110. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
111. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
112. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7
113. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159: 2661-7
114. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92
115. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046-51
116. Collins R, Armitage J, Sleigh P, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16
117. Aguilar-Salinas CA, Barrett H, Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis 1998; 141: 203-7
118. Chan DC, Watts GF, Barrett PHR, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002; 51: 2377-86
119. Watts GF, Chan DC, Barrett PHR, et al. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord 2003 Jul; 27 (7): 862-5
120. Geneieve M, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 2001; 107: 1423-32
121. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105: 1424-8
122. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383-90
123. Qin S, Koga T, Ganji SH, et al. Rosuvastatin stimulates apolipoprotein AI synthesis but not HDL catabolism by cultured human hepatocytes [abstract] 4th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology. May 8-10, 2003, Washington DC, USA. 2003, 255
124. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999; 10: 561-74
125. Fruchart JC, Duriez P. HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 2002; 13: 605-16
126. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 1995; 92: 1779-85
127. The Diabetes Atherosclerosis Intervention Study. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: a randomised study. Lancet 2001; 357: 905-10
128. Fruchart JC, Staels B, Duriez P. PPARs, metabolic disease and atherosclerosis. Pharmacol Res 2001; 44: 345-52
129. Robins SJ. PPARα ligands and clinical trials: cardiovascular risk reduction with fibrates. J Cardiovas Risk 2001; 8: 195-201
130. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atherosclerosis Rep 2001; 3: 83-92
131. Berge J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35
132. Bocher V, Millatt LJ, Fruchart JC, et al. Liver X receptors: new players in atherogenesis? Curr Opin Lipidol 2003; 14: 137-43
133. Forcheron F, Cachefo A, Thevenon S, et al. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002; 51: 3486-91
134. Roglans N, Peris C, Verd JC, et al. Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats. Biochem Pharmacol 2001; 62: 803-9
135. Blane GF. Comparative toxicity and safety profile of fenofibrate and othe fibric acid derivatives. Am J Med 1987; 83: 26-36
136. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
137. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9
138. Grundy SM, Ahrens EH, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78: 94-121
139. Crouse III JR. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987; 83: 243-8
140. Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis. Curr Atherosclerosis Rep 2001; 3: 74-82
141. Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am J Cardiol 1998; 82: 18U-23U
142. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
143. SoRelle R. Niacin-simvastatin combination benefits patients with coronary artery disease. Circulation 2001; 104: E9050-60
144. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000; 2: 26-46
145. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992, 77-81
146. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284: 1263-70
147. Grundy SM, Vega G, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162: 1568-76
148. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002; 277: 8755-8
149. Angerer P, von Schacky C. n-3 polyunsaturated fatty acids and the cardiovascular system. Curr Opin Lipidol 2000; 11: 57-63
150. Nordoy A. Fish consumption and cardiovascular diseases. Eur Heart J 2001; 3: D4-7
151. Harris WS, Isley WL. Clinical trial evidence for the cardioprotective effects of omega-3-fatty acids. Curr Atheroscler Rep 2001; 3: 174-9
152. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-55
153. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 130: 554-62
154. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-85
155. Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr Opin Lipidol 2000; 11: 3-7
156. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002; 76: 1007-15
157. Chan DC, Watts GF, Mori TA, et al. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 2002; 32: 429-36
158. Nestel PJ, Connor WE, Reardon MF, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984; 74: 82-9
159. Bordin P, Bodamer OA, Venkatesan S, et al. Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Eur J Clin Nutr 1998: 52: 104-9
160. Chan DC, Watts GF, Mori TA, et al. Randomized controlled trial of the effect of n-3 fatty acids supplementation on apolipoprotein B-100 and chylomicron remnant metabolism in visceral obesity. Am J Clin Nutr 2003; 77: 300-9
161. Frenais R, Ouguerram K, Maugeais C, et al. Effect of dietary omega-3 fatty acids on high density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis 2001; 157: 131-5
162. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular events reduction. JAMA 1998; 279: 1643-50
163. Jacobson TA. Combination lipid-altering therapy: an emerging treatment paradigm for 21st century. Curr Atheroscler Rep 2001; 3: 373-82
164. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80: 608-13
165. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998; 19: 355-71
166. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672-8
167. Bhatnagar D, Mackness MI, Durrinton PN. Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMG CoA reductase inhibitor. Eur Heart J 2001; 3: D53-8
168. Millatt LJ, Bocher V, Fruchart JC, et al. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochim Biophys Acta 2003; 1631: 107-18
169. Kaplan F, Al-Majali K, Betteridge DJ. PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk 2001; 8: 211-7
170. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33
171. United Kingdom Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854-65
172. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74
173. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group: Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-25
174. Watts GF, Herrmann S, Riches FM. Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men. QJM 2000; 93: 153-61
175. Snider LJ, Malone M. Orlistat use in type 2 diabetes. Ann Pharmacother 2002: 36: 1210-8
176. Clifton P. Plant sterol and stanols-comparison and contrasts: sterol verse stanols in cholesterol-lowering: is there a difference. Atheroscler Suppl 2002; 3 (3): S5-9
177. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res 1996; 37: 1776-85
178. Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994; 37: 773-80
179. Knopp RH, Gitter H, Truitt T. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729-41
180. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717-28
181. Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 2002; 90: 737-40
182. Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vasc Biol 1997; 17: 56-63
183. Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomised phase II dose-response study. Circulation 2002; 105: 2159-65
184. Barter PJ, Rye KA. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipidol 2001; 12: 377-82
185. Izzat NN, Deshazer ME, Loose-Mitchell DS. New molecular targets for cholesterol-lowering therapy. J Pharmacol Exp Ther 2000; 293: 315-20
186. Huff MW, Telford DE, Edwards JY, et al. Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler Thromb Vas Biol 2002; 22: 1884-91
187. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-8
188. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152-62